LIVN — LivaNova PLC

LivaNova PLC Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $362 million, an 11% increase year-over-year on a constant currency basis.
• Adjusted Gross Margin: 68%, down from 69% in Q1 2025.
• Adjusted Operating Income: $71 million, with an operating margin of 20%.
• Adjusted Diluted Earnings Per Share (EPS): $0.98, up from $0.88 in Q1 2025.
• Cash Position: $540 million, down from $636 million at year-end 2025.
• Total Debt: $288 million, reduced from $377 million at year-end 2025.
• Adjusted Free Cash Flow: $4 million, down from $20 million in the prior year.

2. Strategic Updates and Business Highlights

• Revenue Growth Drivers: Strong performance in cardiopulmonary and epilepsy segments, with cardiopulmonary revenue at $209 million (14% growth) and epilepsy revenue up 8%.
• Obstructive Sleep Apnea (OSA) Market: Received FDA premarket approval for the aura6000 system, the first hypoglossal nerve stimulation device approved without contraindications. Planned entry into the OSA market in 2027.
• Epilepsy Segment: Improved reimbursement rates for VNS therapy effective January 1, 2026, leading to higher pricing and increased procedure volumes.
• Innovation Pipeline: Continued focus on developing next-generation products, including a new oxygenator and cloud-based clinician portal for epilepsy.

3. Forward Guidance and Outlook

• 2026 Revenue Growth Guidance: Increased to 7% to 8% from a previous range of 6% to 7%.
• Adjusted EPS Guidance: Projected between $4.20 to $4.30, reflecting approximately 9% growth at midpoint.
• Adjusted Free Cash Flow: Expected to remain in the range of $160 million to $180 million.
• Cardiopulmonary Revenue Growth: Now expected to grow 8.5% to 9.5%, up from 7% to 8%.

4. Bad News, Challenges, or Points of Concern

• Foreign Exchange Impact: Approximately $10 million favorable impact on revenue, but potential risks remain.
• Middle East Conflict: Estimated $5 million adverse impact on adjusted operating income due to increased shipping and logistics costs.
• Challenges in the Hypoglossal Nerve Stimulation (HGNS) Market: Current reimbursement dynamics viewed as temporary, but ongoing ambiguity remains a concern.
• Competitive Pressures: Some competitors are exiting the market, but LivaNova must continue to innovate to maintain its market position.

5. Notable Q&A Insights

• Epilepsy Business: Analysts expressed optimism about the impact of improved reimbursement on VNS therapy adoption, with expectations for increased pricing and procedure volumes.
• Cardiopulmonary Segment: Confidence in manufacturing capacity improvements and market share gains, with a focus on increasing oxygenator production.
• OSA Launch Strategy: Preparations for the OSA market entry are underway, with hiring for the sales force expected to begin in late 2026 or early 2027.
• Generalized Seizure Landscape: Anticipated competition in the neuromodulation space, but LivaNova expects limited impact on its market share.

Overall, LivaNova reported a strong start to 2026 with robust revenue growth and strategic advancements, particularly in the epilepsy and cardiopulmonary segments, while navigating challenges related to market dynamics and external factors.